Can dapagliflozin (Farxiga) be started in an 84-year-old female with an estimated glomerular filtration rate of 32 mL/min/1.73 m²?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, dapagliflozin (Farxiga) can be started in this 84-year-old female with an eGFR of 32 mL/min/1.73 m²

Based on the most recent 2022 ADA/KDIGO consensus guidelines, SGLT2 inhibitors with proven kidney or cardiovascular benefit are recommended for patients with type 2 diabetes, CKD, and eGFR ≥20 mL/min/1.73 m² 1. With an eGFR of 32 mL/min/1.73 m², this patient falls well within the recommended initiation range.

Key Evidence Supporting Initiation

The 2022 KDIGO guideline specifically updated the lower eGFR threshold for SGLT2i initiation from ≥30 to ≥20 mL/min/1.73 m², driven by robust trial data including DAPA-CKD 1. Dapagliflozin is FDA-approved for use at 10 mg once daily with eGFR of 25 to <45 mL/min/1.73 m² 1, 2.

The landmark DAPA-CKD trial demonstrated that dapagliflozin significantly reduced the composite risk of sustained eGFR decline ≥50%, end-stage kidney disease, or cardiovascular/renal death (HR 0.61,95% CI 0.51-0.72, p<0.001) in patients with eGFR 25-75 mL/min/1.73 m² 3. Importantly, efficacy and safety were consistent across age groups, including septuagenarians and octogenarians who comprised 25% of participants 4.

Dosing and Monitoring

  • Start with dapagliflozin 10 mg once daily 1
  • Expect an initial reversible eGFR decline of 3-5 mL/min/1.73 m² within the first 2-4 weeks 5, 6
  • Continue therapy even if eGFR drops below 25 mL/min/1.73 m² after initiation, as the drug can be maintained until dialysis 1
  • Monitor volume status and renal function after initiation, particularly in elderly patients 2

Critical Risk Mitigation Strategies

Given her age and eGFR, implement these specific precautions:

Volume depletion risk:

  • Assess volume status before initiation 2
  • Consider proactive diuretic dose reduction if she's on loop diuretics 1, 5
  • Monitor for signs of hypotension after starting therapy

Genital mycotic infections:

  • Counsel on daily genital hygiene measures 1
  • Risk is higher in women (6% vs 1% placebo) 1
  • Most infections are easily treated, but monitor for severe cases

Sick day protocol:

  • Hold dapagliflozin during acute illness (nausea, vomiting, diarrhea, reduced oral intake) 1, 5
  • Resume when clinically stable and oral intake restored
  • Educate on ketoacidosis signs (though risk is lower without type 1 diabetes)

Hypoglycemia:

  • If on insulin or sulfonylureas, reduce doses to minimize hypoglycemia risk 1
  • Maintain at least low-dose insulin if insulin-requiring to prevent ketoacidosis 1

Important Caveats

Do not initiate if:

  • eGFR <25 mL/min/1.73 m² per FDA labeling (though guidelines support ≥20) 1, 2
  • Polycystic kidney disease or recent immunosuppressive therapy for kidney disease 2
  • Active ketoacidosis or severe volume depletion 2

The initial eGFR dip is expected and not a reason to discontinue 1, 5. Both CREDENCE and DAPA-CKD protocols specified continuation when eGFR fell below initiation thresholds 1. The drug provides kidney and cardiovascular protection independent of glucose-lowering effects at this eGFR level 7, 1.

Age alone should not be a barrier - therapeutic nihilism or ageism should not discourage use in octogenarians who are likely to experience considerable benefit from reduced mortality, cardiovascular events, and CKD progression 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.